70/30 it gets approval. If not, look out below. Not huge upside with approval as real money is in longer term chronic oral dosing and enough doubts have been raised over short term safety issues with the IV formulation. Good drug with reasonable market but not a homerun.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.